Global Long-acting Retinal Drugs Market Research Report 2026(Status and Outlook)
Long-acting retinal drugs are pharmaceutical agents designed to provide prolonged therapeutic effects in the retina, reducing the frequency of administrations required for eye diseases. These drugs typically utilize advanced delivery systems (such as sustained-release implants, biodegradable polymers, or viral vectors) to maintain therapeutic concentrations in the ocular tissue over extended periods (months to years). They target retinal disorders like age-related macular degeneration (AMD), diabetic retinopathy, and retinal vascular diseases, aiming to minimize patient discomfort, improve compliance, and prevent vision loss by sustaining effective drug action without repeated injections or topical applications.
The global Long-acting Retinal Drugs market size was estimated at USD 2530.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 6.90% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Long-acting Retinal Drugs market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Long-acting Retinal Drugs market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Long-acting Retinal Drugs market.
Global Long-acting Retinal Drugs Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Bayer
F. Hoffmann-La Roche
Novartis
Regeneron
Merck
Takeda
Teva Pharmaceutical
ThromboGenics
Janssen Pharmaceuticals (Johnson & Johnson)
Oxurion NV
Allergan
MeiraGTx Limited
OncoGene Pharmaceuticals
AbbVie Inc.
Alcon Inc.
Alimera Sciences Inc.
Bausch Health Co. Inc.
Market Segmentation (by Type)
Chemically Synthesized Drugs
Biologics
Natural/Nutritional Supplements
Market Segmentation (by Application)
Hospital
Clinic
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Long-acting Retinal Drugs Market
Overview of the regional outlook of the Long-acting Retinal Drugs Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Long-acting Retinal Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Long-acting Retinal Drugs, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global Long-acting Retinal Drugs market size was estimated at USD 2530.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 6.90% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Long-acting Retinal Drugs market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Long-acting Retinal Drugs market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Long-acting Retinal Drugs market.
Global Long-acting Retinal Drugs Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Bayer
F. Hoffmann-La Roche
Novartis
Regeneron
Merck
Takeda
Teva Pharmaceutical
ThromboGenics
Janssen Pharmaceuticals (Johnson & Johnson)
Oxurion NV
Allergan
MeiraGTx Limited
OncoGene Pharmaceuticals
AbbVie Inc.
Alcon Inc.
Alimera Sciences Inc.
Bausch Health Co. Inc.
Market Segmentation (by Type)
Chemically Synthesized Drugs
Biologics
Natural/Nutritional Supplements
Market Segmentation (by Application)
Hospital
Clinic
Other
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Long-acting Retinal Drugs Market
Overview of the regional outlook of the Long-acting Retinal Drugs Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Long-acting Retinal Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Long-acting Retinal Drugs, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Long-acting Retinal Drugs
1.2 Key Market Segments
1.2.1 Long-acting Retinal Drugs Segment by Type
1.2.2 Long-acting Retinal Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 LONG-ACTING RETINAL DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Long-acting Retinal Drugs Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Long-acting Retinal Drugs Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 LONG-ACTING RETINAL DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Long-acting Retinal Drugs Product Life Cycle
3.3 Global Long-acting Retinal Drugs Sales by Manufacturers (2020-2025)
3.4 Global Long-acting Retinal Drugs Revenue Market Share by Manufacturers (2020-2025)
3.5 Long-acting Retinal Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Long-acting Retinal Drugs Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Long-acting Retinal Drugs Market Competitive Situation and Trends
3.8.1 Long-acting Retinal Drugs Market Concentration Rate
3.8.2 Global 5 and 10 Largest Long-acting Retinal Drugs Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 LONG-ACTING RETINAL DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Long-acting Retinal Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF LONG-ACTING RETINAL DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Long-acting Retinal Drugs Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Long-acting Retinal Drugs Market
5.7 ESG Ratings of Leading Companies
6 LONG-ACTING RETINAL DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Long-acting Retinal Drugs Sales Market Share by Type (2020-2025)
6.3 Global Long-acting Retinal Drugs Market Size by Type (2020-2025)
6.4 Global Long-acting Retinal Drugs Price by Type (2020-2025)
7 LONG-ACTING RETINAL DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Long-acting Retinal Drugs Market Sales by Application (2020-2025)
7.3 Global Long-acting Retinal Drugs Market Size (M USD) by Application (2020-2025)
7.4 Global Long-acting Retinal Drugs Sales Growth Rate by Application (2020-2025)
8 LONG-ACTING RETINAL DRUGS MARKET SALES BY REGION
8.1 Global Long-acting Retinal Drugs Sales by Region
8.1.1 Global Long-acting Retinal Drugs Sales by Region
8.1.2 Global Long-acting Retinal Drugs Sales Market Share by Region
8.2 Global Long-acting Retinal Drugs Market Size by Region
8.2.1 Global Long-acting Retinal Drugs Market Size by Region
8.2.2 Global Long-acting Retinal Drugs Market Size by Region
8.3 North America
8.3.1 North America Long-acting Retinal Drugs Sales by Country
8.3.2 North America Long-acting Retinal Drugs Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Long-acting Retinal Drugs Sales by Country
8.4.2 Europe Long-acting Retinal Drugs Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Long-acting Retinal Drugs Sales by Region
8.5.2 Asia Pacific Long-acting Retinal Drugs Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Long-acting Retinal Drugs Sales by Country
8.6.2 South America Long-acting Retinal Drugs Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Long-acting Retinal Drugs Sales by Region
8.7.2 Middle East and Africa Long-acting Retinal Drugs Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 LONG-ACTING RETINAL DRUGS MARKET PRODUCTION BY REGION
9.1 Global Production of Long-acting Retinal Drugs by Region(2020-2025)
9.2 Global Long-acting Retinal Drugs Revenue Market Share by Region (2020-2025)
9.3 Global Long-acting Retinal Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Long-acting Retinal Drugs Production
9.4.1 North America Long-acting Retinal Drugs Production Growth Rate (2020-2025)
9.4.2 North America Long-acting Retinal Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Long-acting Retinal Drugs Production
9.5.1 Europe Long-acting Retinal Drugs Production Growth Rate (2020-2025)
9.5.2 Europe Long-acting Retinal Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Long-acting Retinal Drugs Production (2020-2025)
9.6.1 Japan Long-acting Retinal Drugs Production Growth Rate (2020-2025)
9.6.2 Japan Long-acting Retinal Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Long-acting Retinal Drugs Production (2020-2025)
9.7.1 China Long-acting Retinal Drugs Production Growth Rate (2020-2025)
9.7.2 China Long-acting Retinal Drugs Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Bayer
10.1.1 Bayer Basic Information
10.1.2 Bayer Long-acting Retinal Drugs Product Overview
10.1.3 Bayer Long-acting Retinal Drugs Product Market Performance
10.1.4 Bayer Business Overview
10.1.5 Bayer SWOT Analysis
10.1.6 Bayer Recent Developments
10.2 F. Hoffmann-La Roche
10.2.1 F. Hoffmann-La Roche Basic Information
10.2.2 F. Hoffmann-La Roche Long-acting Retinal Drugs Product Overview
10.2.3 F. Hoffmann-La Roche Long-acting Retinal Drugs Product Market Performance
10.2.4 F. Hoffmann-La Roche Business Overview
10.2.5 F. Hoffmann-La Roche SWOT Analysis
10.2.6 F. Hoffmann-La Roche Recent Developments
10.3 Novartis
10.3.1 Novartis Basic Information
10.3.2 Novartis Long-acting Retinal Drugs Product Overview
10.3.3 Novartis Long-acting Retinal Drugs Product Market Performance
10.3.4 Novartis Business Overview
10.3.5 Novartis SWOT Analysis
10.3.6 Novartis Recent Developments
10.4 Regeneron
10.4.1 Regeneron Basic Information
10.4.2 Regeneron Long-acting Retinal Drugs Product Overview
10.4.3 Regeneron Long-acting Retinal Drugs Product Market Performance
10.4.4 Regeneron Business Overview
10.4.5 Regeneron Recent Developments
10.5 Merck
10.5.1 Merck Basic Information
10.5.2 Merck Long-acting Retinal Drugs Product Overview
10.5.3 Merck Long-acting Retinal Drugs Product Market Performance
10.5.4 Merck Business Overview
10.5.5 Merck Recent Developments
10.6 Takeda
10.6.1 Takeda Basic Information
10.6.2 Takeda Long-acting Retinal Drugs Product Overview
10.6.3 Takeda Long-acting Retinal Drugs Product Market Performance
10.6.4 Takeda Business Overview
10.6.5 Takeda Recent Developments
10.7 Teva Pharmaceutical
10.7.1 Teva Pharmaceutical Basic Information
10.7.2 Teva Pharmaceutical Long-acting Retinal Drugs Product Overview
10.7.3 Teva Pharmaceutical Long-acting Retinal Drugs Product Market Performance
10.7.4 Teva Pharmaceutical Business Overview
10.7.5 Teva Pharmaceutical Recent Developments
10.8 ThromboGenics
10.8.1 ThromboGenics Basic Information
10.8.2 ThromboGenics Long-acting Retinal Drugs Product Overview
10.8.3 ThromboGenics Long-acting Retinal Drugs Product Market Performance
10.8.4 ThromboGenics Business Overview
10.8.5 ThromboGenics Recent Developments
10.9 Janssen Pharmaceuticals (Johnson and Johnson)
10.9.1 Janssen Pharmaceuticals (Johnson and Johnson) Basic Information
10.9.2 Janssen Pharmaceuticals (Johnson and Johnson) Long-acting Retinal Drugs Product Overview
10.9.3 Janssen Pharmaceuticals (Johnson and Johnson) Long-acting Retinal Drugs Product Market Performance
10.9.4 Janssen Pharmaceuticals (Johnson and Johnson) Business Overview
10.9.5 Janssen Pharmaceuticals (Johnson and Johnson) Recent Developments
10.10 Oxurion NV
10.10.1 Oxurion NV Basic Information
10.10.2 Oxurion NV Long-acting Retinal Drugs Product Overview
10.10.3 Oxurion NV Long-acting Retinal Drugs Product Market Performance
10.10.4 Oxurion NV Business Overview
10.10.5 Oxurion NV Recent Developments
10.11 Allergan
10.11.1 Allergan Basic Information
10.11.2 Allergan Long-acting Retinal Drugs Product Overview
10.11.3 Allergan Long-acting Retinal Drugs Product Market Performance
10.11.4 Allergan Business Overview
10.11.5 Allergan Recent Developments
10.12 MeiraGTx Limited
10.12.1 MeiraGTx Limited Basic Information
10.12.2 MeiraGTx Limited Long-acting Retinal Drugs Product Overview
10.12.3 MeiraGTx Limited Long-acting Retinal Drugs Product Market Performance
10.12.4 MeiraGTx Limited Business Overview
10.12.5 MeiraGTx Limited Recent Developments
10.13 OncoGene Pharmaceuticals
10.13.1 OncoGene Pharmaceuticals Basic Information
10.13.2 OncoGene Pharmaceuticals Long-acting Retinal Drugs Product Overview
10.13.3 OncoGene Pharmaceuticals Long-acting Retinal Drugs Product Market Performance
10.13.4 OncoGene Pharmaceuticals Business Overview
10.13.5 OncoGene Pharmaceuticals Recent Developments
10.14 AbbVie Inc.
10.14.1 AbbVie Inc. Basic Information
10.14.2 AbbVie Inc. Long-acting Retinal Drugs Product Overview
10.14.3 AbbVie Inc. Long-acting Retinal Drugs Product Market Performance
10.14.4 AbbVie Inc. Business Overview
10.14.5 AbbVie Inc. Recent Developments
10.15 Alcon Inc.
10.15.1 Alcon Inc. Basic Information
10.15.2 Alcon Inc. Long-acting Retinal Drugs Product Overview
10.15.3 Alcon Inc. Long-acting Retinal Drugs Product Market Performance
10.15.4 Alcon Inc. Business Overview
10.15.5 Alcon Inc. Recent Developments
10.16 Alimera Sciences Inc.
10.16.1 Alimera Sciences Inc. Basic Information
10.16.2 Alimera Sciences Inc. Long-acting Retinal Drugs Product Overview
10.16.3 Alimera Sciences Inc. Long-acting Retinal Drugs Product Market Performance
10.16.4 Alimera Sciences Inc. Business Overview
10.16.5 Alimera Sciences Inc. Recent Developments
10.17 Bausch Health Co. Inc.
10.17.1 Bausch Health Co. Inc. Basic Information
10.17.2 Bausch Health Co. Inc. Long-acting Retinal Drugs Product Overview
10.17.3 Bausch Health Co. Inc. Long-acting Retinal Drugs Product Market Performance
10.17.4 Bausch Health Co. Inc. Business Overview
10.17.5 Bausch Health Co. Inc. Recent Developments
11 LONG-ACTING RETINAL DRUGS MARKET FORECAST BY REGION
11.1 Global Long-acting Retinal Drugs Market Size Forecast
11.2 Global Long-acting Retinal Drugs Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Long-acting Retinal Drugs Market Size Forecast by Country
11.2.3 Asia Pacific Long-acting Retinal Drugs Market Size Forecast by Region
11.2.4 South America Long-acting Retinal Drugs Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Long-acting Retinal Drugs by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Long-acting Retinal Drugs Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Long-acting Retinal Drugs by Type (2026-2035)
12.1.2 Global Long-acting Retinal Drugs Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Long-acting Retinal Drugs by Type (2026-2035)
12.2 Global Long-acting Retinal Drugs Market Forecast by Application (2026-2035)
12.2.1 Global Long-acting Retinal Drugs Sales (K MT) Forecast by Application
12.2.2 Global Long-acting Retinal Drugs Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Long-acting Retinal Drugs
1.2 Key Market Segments
1.2.1 Long-acting Retinal Drugs Segment by Type
1.2.2 Long-acting Retinal Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 LONG-ACTING RETINAL DRUGS MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Long-acting Retinal Drugs Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Long-acting Retinal Drugs Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 LONG-ACTING RETINAL DRUGS MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global Long-acting Retinal Drugs Product Life Cycle
3.3 Global Long-acting Retinal Drugs Sales by Manufacturers (2020-2025)
3.4 Global Long-acting Retinal Drugs Revenue Market Share by Manufacturers (2020-2025)
3.5 Long-acting Retinal Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Long-acting Retinal Drugs Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 Long-acting Retinal Drugs Market Competitive Situation and Trends
3.8.1 Long-acting Retinal Drugs Market Concentration Rate
3.8.2 Global 5 and 10 Largest Long-acting Retinal Drugs Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 LONG-ACTING RETINAL DRUGS INDUSTRY CHAIN ANALYSIS
4.1 Long-acting Retinal Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF LONG-ACTING RETINAL DRUGS MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Long-acting Retinal Drugs Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to Long-acting Retinal Drugs Market
5.7 ESG Ratings of Leading Companies
6 LONG-ACTING RETINAL DRUGS MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Long-acting Retinal Drugs Sales Market Share by Type (2020-2025)
6.3 Global Long-acting Retinal Drugs Market Size by Type (2020-2025)
6.4 Global Long-acting Retinal Drugs Price by Type (2020-2025)
7 LONG-ACTING RETINAL DRUGS MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Long-acting Retinal Drugs Market Sales by Application (2020-2025)
7.3 Global Long-acting Retinal Drugs Market Size (M USD) by Application (2020-2025)
7.4 Global Long-acting Retinal Drugs Sales Growth Rate by Application (2020-2025)
8 LONG-ACTING RETINAL DRUGS MARKET SALES BY REGION
8.1 Global Long-acting Retinal Drugs Sales by Region
8.1.1 Global Long-acting Retinal Drugs Sales by Region
8.1.2 Global Long-acting Retinal Drugs Sales Market Share by Region
8.2 Global Long-acting Retinal Drugs Market Size by Region
8.2.1 Global Long-acting Retinal Drugs Market Size by Region
8.2.2 Global Long-acting Retinal Drugs Market Size by Region
8.3 North America
8.3.1 North America Long-acting Retinal Drugs Sales by Country
8.3.2 North America Long-acting Retinal Drugs Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Long-acting Retinal Drugs Sales by Country
8.4.2 Europe Long-acting Retinal Drugs Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Long-acting Retinal Drugs Sales by Region
8.5.2 Asia Pacific Long-acting Retinal Drugs Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Long-acting Retinal Drugs Sales by Country
8.6.2 South America Long-acting Retinal Drugs Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Long-acting Retinal Drugs Sales by Region
8.7.2 Middle East and Africa Long-acting Retinal Drugs Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 LONG-ACTING RETINAL DRUGS MARKET PRODUCTION BY REGION
9.1 Global Production of Long-acting Retinal Drugs by Region(2020-2025)
9.2 Global Long-acting Retinal Drugs Revenue Market Share by Region (2020-2025)
9.3 Global Long-acting Retinal Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Long-acting Retinal Drugs Production
9.4.1 North America Long-acting Retinal Drugs Production Growth Rate (2020-2025)
9.4.2 North America Long-acting Retinal Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Long-acting Retinal Drugs Production
9.5.1 Europe Long-acting Retinal Drugs Production Growth Rate (2020-2025)
9.5.2 Europe Long-acting Retinal Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Long-acting Retinal Drugs Production (2020-2025)
9.6.1 Japan Long-acting Retinal Drugs Production Growth Rate (2020-2025)
9.6.2 Japan Long-acting Retinal Drugs Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Long-acting Retinal Drugs Production (2020-2025)
9.7.1 China Long-acting Retinal Drugs Production Growth Rate (2020-2025)
9.7.2 China Long-acting Retinal Drugs Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Bayer
10.1.1 Bayer Basic Information
10.1.2 Bayer Long-acting Retinal Drugs Product Overview
10.1.3 Bayer Long-acting Retinal Drugs Product Market Performance
10.1.4 Bayer Business Overview
10.1.5 Bayer SWOT Analysis
10.1.6 Bayer Recent Developments
10.2 F. Hoffmann-La Roche
10.2.1 F. Hoffmann-La Roche Basic Information
10.2.2 F. Hoffmann-La Roche Long-acting Retinal Drugs Product Overview
10.2.3 F. Hoffmann-La Roche Long-acting Retinal Drugs Product Market Performance
10.2.4 F. Hoffmann-La Roche Business Overview
10.2.5 F. Hoffmann-La Roche SWOT Analysis
10.2.6 F. Hoffmann-La Roche Recent Developments
10.3 Novartis
10.3.1 Novartis Basic Information
10.3.2 Novartis Long-acting Retinal Drugs Product Overview
10.3.3 Novartis Long-acting Retinal Drugs Product Market Performance
10.3.4 Novartis Business Overview
10.3.5 Novartis SWOT Analysis
10.3.6 Novartis Recent Developments
10.4 Regeneron
10.4.1 Regeneron Basic Information
10.4.2 Regeneron Long-acting Retinal Drugs Product Overview
10.4.3 Regeneron Long-acting Retinal Drugs Product Market Performance
10.4.4 Regeneron Business Overview
10.4.5 Regeneron Recent Developments
10.5 Merck
10.5.1 Merck Basic Information
10.5.2 Merck Long-acting Retinal Drugs Product Overview
10.5.3 Merck Long-acting Retinal Drugs Product Market Performance
10.5.4 Merck Business Overview
10.5.5 Merck Recent Developments
10.6 Takeda
10.6.1 Takeda Basic Information
10.6.2 Takeda Long-acting Retinal Drugs Product Overview
10.6.3 Takeda Long-acting Retinal Drugs Product Market Performance
10.6.4 Takeda Business Overview
10.6.5 Takeda Recent Developments
10.7 Teva Pharmaceutical
10.7.1 Teva Pharmaceutical Basic Information
10.7.2 Teva Pharmaceutical Long-acting Retinal Drugs Product Overview
10.7.3 Teva Pharmaceutical Long-acting Retinal Drugs Product Market Performance
10.7.4 Teva Pharmaceutical Business Overview
10.7.5 Teva Pharmaceutical Recent Developments
10.8 ThromboGenics
10.8.1 ThromboGenics Basic Information
10.8.2 ThromboGenics Long-acting Retinal Drugs Product Overview
10.8.3 ThromboGenics Long-acting Retinal Drugs Product Market Performance
10.8.4 ThromboGenics Business Overview
10.8.5 ThromboGenics Recent Developments
10.9 Janssen Pharmaceuticals (Johnson and Johnson)
10.9.1 Janssen Pharmaceuticals (Johnson and Johnson) Basic Information
10.9.2 Janssen Pharmaceuticals (Johnson and Johnson) Long-acting Retinal Drugs Product Overview
10.9.3 Janssen Pharmaceuticals (Johnson and Johnson) Long-acting Retinal Drugs Product Market Performance
10.9.4 Janssen Pharmaceuticals (Johnson and Johnson) Business Overview
10.9.5 Janssen Pharmaceuticals (Johnson and Johnson) Recent Developments
10.10 Oxurion NV
10.10.1 Oxurion NV Basic Information
10.10.2 Oxurion NV Long-acting Retinal Drugs Product Overview
10.10.3 Oxurion NV Long-acting Retinal Drugs Product Market Performance
10.10.4 Oxurion NV Business Overview
10.10.5 Oxurion NV Recent Developments
10.11 Allergan
10.11.1 Allergan Basic Information
10.11.2 Allergan Long-acting Retinal Drugs Product Overview
10.11.3 Allergan Long-acting Retinal Drugs Product Market Performance
10.11.4 Allergan Business Overview
10.11.5 Allergan Recent Developments
10.12 MeiraGTx Limited
10.12.1 MeiraGTx Limited Basic Information
10.12.2 MeiraGTx Limited Long-acting Retinal Drugs Product Overview
10.12.3 MeiraGTx Limited Long-acting Retinal Drugs Product Market Performance
10.12.4 MeiraGTx Limited Business Overview
10.12.5 MeiraGTx Limited Recent Developments
10.13 OncoGene Pharmaceuticals
10.13.1 OncoGene Pharmaceuticals Basic Information
10.13.2 OncoGene Pharmaceuticals Long-acting Retinal Drugs Product Overview
10.13.3 OncoGene Pharmaceuticals Long-acting Retinal Drugs Product Market Performance
10.13.4 OncoGene Pharmaceuticals Business Overview
10.13.5 OncoGene Pharmaceuticals Recent Developments
10.14 AbbVie Inc.
10.14.1 AbbVie Inc. Basic Information
10.14.2 AbbVie Inc. Long-acting Retinal Drugs Product Overview
10.14.3 AbbVie Inc. Long-acting Retinal Drugs Product Market Performance
10.14.4 AbbVie Inc. Business Overview
10.14.5 AbbVie Inc. Recent Developments
10.15 Alcon Inc.
10.15.1 Alcon Inc. Basic Information
10.15.2 Alcon Inc. Long-acting Retinal Drugs Product Overview
10.15.3 Alcon Inc. Long-acting Retinal Drugs Product Market Performance
10.15.4 Alcon Inc. Business Overview
10.15.5 Alcon Inc. Recent Developments
10.16 Alimera Sciences Inc.
10.16.1 Alimera Sciences Inc. Basic Information
10.16.2 Alimera Sciences Inc. Long-acting Retinal Drugs Product Overview
10.16.3 Alimera Sciences Inc. Long-acting Retinal Drugs Product Market Performance
10.16.4 Alimera Sciences Inc. Business Overview
10.16.5 Alimera Sciences Inc. Recent Developments
10.17 Bausch Health Co. Inc.
10.17.1 Bausch Health Co. Inc. Basic Information
10.17.2 Bausch Health Co. Inc. Long-acting Retinal Drugs Product Overview
10.17.3 Bausch Health Co. Inc. Long-acting Retinal Drugs Product Market Performance
10.17.4 Bausch Health Co. Inc. Business Overview
10.17.5 Bausch Health Co. Inc. Recent Developments
11 LONG-ACTING RETINAL DRUGS MARKET FORECAST BY REGION
11.1 Global Long-acting Retinal Drugs Market Size Forecast
11.2 Global Long-acting Retinal Drugs Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Long-acting Retinal Drugs Market Size Forecast by Country
11.2.3 Asia Pacific Long-acting Retinal Drugs Market Size Forecast by Region
11.2.4 South America Long-acting Retinal Drugs Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Long-acting Retinal Drugs by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global Long-acting Retinal Drugs Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Long-acting Retinal Drugs by Type (2026-2035)
12.1.2 Global Long-acting Retinal Drugs Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Long-acting Retinal Drugs by Type (2026-2035)
12.2 Global Long-acting Retinal Drugs Market Forecast by Application (2026-2035)
12.2.1 Global Long-acting Retinal Drugs Sales (K MT) Forecast by Application
12.2.2 Global Long-acting Retinal Drugs Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Long-acting Retinal Drugs Market Size by Type (M USD)
Table 4. Global Long-acting Retinal Drugs Market Size by Application
Table 5. Long-acting Retinal Drugs Market Size Comparison by Region (M USD)
Table 6. Global Long-acting Retinal Drugs Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Long-acting Retinal Drugs Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Long-acting Retinal Drugs Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Long-acting Retinal Drugs Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting Retinal Drugs as of 2025)
Table 11. Global Market Long-acting Retinal Drugs Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Long-acting Retinal Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Long-acting Retinal Drugs Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Long-acting Retinal Drugs Sales by Type (K MT)
Table 27. Global Long-acting Retinal Drugs Market Size by Type (M USD)
Table 28. Global Long-acting Retinal Drugs Sales (K MT) by Type (2020-2025)
Table 29. Global Long-acting Retinal Drugs Sales Market Share by Type (2020-2025)
Table 30. Global Long-acting Retinal Drugs Market Size (M USD) by Type (2020-2025)
Table 31. Global Long-acting Retinal Drugs Market Share by Type (2020-2025)
Table 32. Global Long-acting Retinal Drugs Price (USD/KG) by Type (2020-2025)
Table 33. Global Long-acting Retinal Drugs Sales (K MT) by Application
Table 34. Global Long-acting Retinal Drugs Market Size by Application
Table 35. Global Long-acting Retinal Drugs Sales by Application (2020-2025) & (K MT)
Table 36. Global Long-acting Retinal Drugs Sales Market Share by Application (2020-2025)
Table 37. Global Long-acting Retinal Drugs Market Size by Application (2020-2025) & (M USD)
Table 38. Global Long-acting Retinal Drugs Market Share by Application (2020-2025)
Table 39. Global Long-acting Retinal Drugs Sales Growth Rate by Application (2020-2025)
Table 40. Global Long-acting Retinal Drugs Sales by Region (2020-2025) & (K MT)
Table 41. Global Long-acting Retinal Drugs Sales Market Share by Region (2020-2025)
Table 42. Global Long-acting Retinal Drugs Market Size by Region (2020-2025) & (M USD)
Table 43. Global Long-acting Retinal Drugs Market Size by Region (2020-2025)
Table 44. North America Long-acting Retinal Drugs Sales by Country (2020-2025) & (K MT)
Table 45. North America Long-acting Retinal Drugs Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Long-acting Retinal Drugs Sales by Country (2020-2025) & (K MT)
Table 47. Europe Long-acting Retinal Drugs Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Long-acting Retinal Drugs Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Long-acting Retinal Drugs Market Size by Region (2020-2025) & (M USD)
Table 50. South America Long-acting Retinal Drugs Sales by Country (2020-2025) & (K MT)
Table 51. South America Long-acting Retinal Drugs Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Long-acting Retinal Drugs Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Long-acting Retinal Drugs Market Size by Region (2020-2025) & (M USD)
Table 54. Global Long-acting Retinal Drugs Production (K MT) by Region(2020-2025)
Table 55. Global Long-acting Retinal Drugs Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Long-acting Retinal Drugs Revenue Market Share by Region (2020-2025)
Table 57. Global Long-acting Retinal Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Long-acting Retinal Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Long-acting Retinal Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Long-acting Retinal Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Long-acting Retinal Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Bayer Basic Information
Table 63. Bayer Long-acting Retinal Drugs Product Overview
Table 64. Bayer Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Bayer Business Overview
Table 66. Bayer SWOT Analysis
Table 67. Bayer Recent Developments
Table 68. F. Hoffmann-La Roche Basic Information
Table 69. F. Hoffmann-La Roche Long-acting Retinal Drugs Product Overview
Table 70. F. Hoffmann-La Roche Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. F. Hoffmann-La Roche Business Overview
Table 72. F. Hoffmann-La Roche SWOT Analysis
Table 73. F. Hoffmann-La Roche Recent Developments
Table 74. Novartis Basic Information
Table 75. Novartis Long-acting Retinal Drugs Product Overview
Table 76. Novartis Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Novartis Business Overview
Table 78. Novartis SWOT Analysis
Table 79. Novartis Recent Developments
Table 80. Regeneron Basic Information
Table 81. Regeneron Long-acting Retinal Drugs Product Overview
Table 82. Regeneron Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Regeneron Business Overview
Table 84. Regeneron Recent Developments
Table 85. Merck Basic Information
Table 86. Merck Long-acting Retinal Drugs Product Overview
Table 87. Merck Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Merck Business Overview
Table 89. Merck Recent Developments
Table 90. Takeda Basic Information
Table 91. Takeda Long-acting Retinal Drugs Product Overview
Table 92. Takeda Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Takeda Business Overview
Table 94. Takeda Recent Developments
Table 95. Teva Pharmaceutical Basic Information
Table 96. Teva Pharmaceutical Long-acting Retinal Drugs Product Overview
Table 97. Teva Pharmaceutical Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Teva Pharmaceutical Business Overview
Table 99. Teva Pharmaceutical Recent Developments
Table 100. ThromboGenics Basic Information
Table 101. ThromboGenics Long-acting Retinal Drugs Product Overview
Table 102. ThromboGenics Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. ThromboGenics Business Overview
Table 104. ThromboGenics Recent Developments
Table 105. Janssen Pharmaceuticals (Johnson and Johnson) Basic Information
Table 106. Janssen Pharmaceuticals (Johnson and Johnson) Long-acting Retinal Drugs Product Overview
Table 107. Janssen Pharmaceuticals (Johnson and Johnson) Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Janssen Pharmaceuticals (Johnson and Johnson) Business Overview
Table 109. Janssen Pharmaceuticals (Johnson and Johnson) Recent Developments
Table 110. Oxurion NV Basic Information
Table 111. Oxurion NV Long-acting Retinal Drugs Product Overview
Table 112. Oxurion NV Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. Oxurion NV Business Overview
Table 114. Oxurion NV Recent Developments
Table 115. Allergan Basic Information
Table 116. Allergan Long-acting Retinal Drugs Product Overview
Table 117. Allergan Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Allergan Business Overview
Table 119. Allergan Recent Developments
Table 120. MeiraGTx Limited Basic Information
Table 121. MeiraGTx Limited Long-acting Retinal Drugs Product Overview
Table 122. MeiraGTx Limited Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. MeiraGTx Limited Business Overview
Table 124. MeiraGTx Limited Recent Developments
Table 125. OncoGene Pharmaceuticals Basic Information
Table 126. OncoGene Pharmaceuticals Long-acting Retinal Drugs Product Overview
Table 127. OncoGene Pharmaceuticals Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. OncoGene Pharmaceuticals Business Overview
Table 129. OncoGene Pharmaceuticals Recent Developments
Table 130. AbbVie Inc. Basic Information
Table 131. AbbVie Inc. Long-acting Retinal Drugs Product Overview
Table 132. AbbVie Inc. Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 133. AbbVie Inc. Business Overview
Table 134. AbbVie Inc. Recent Developments
Table 135. Alcon Inc. Basic Information
Table 136. Alcon Inc. Long-acting Retinal Drugs Product Overview
Table 137. Alcon Inc. Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 138. Alcon Inc. Business Overview
Table 139. Alcon Inc. Recent Developments
Table 140. Alimera Sciences Inc. Basic Information
Table 141. Alimera Sciences Inc. Long-acting Retinal Drugs Product Overview
Table 142. Alimera Sciences Inc. Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 143. Alimera Sciences Inc. Business Overview
Table 144. Alimera Sciences Inc. Recent Developments
Table 145. Bausch Health Co. Inc. Basic Information
Table 146. Bausch Health Co. Inc. Long-acting Retinal Drugs Product Overview
Table 147. Bausch Health Co. Inc. Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 148. Bausch Health Co. Inc. Business Overview
Table 149. Bausch Health Co. Inc. Recent Developments
Table 150. Global Long-acting Retinal Drugs Sales Forecast by Region (2026-2035) & (K MT)
Table 151. Global Long-acting Retinal Drugs Market Size Forecast by Region (2026-2035) & (M USD)
Table 152. North America Long-acting Retinal Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 153. North America Long-acting Retinal Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 154. Europe Long-acting Retinal Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 155. Europe Long-acting Retinal Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 156. Asia Pacific Long-acting Retinal Drugs Sales Forecast by Region (2026-2035) & (K MT)
Table 157. Asia Pacific Long-acting Retinal Drugs Market Size Forecast by Region (2026-2035) & (M USD)
Table 158. South America Long-acting Retinal Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 159. South America Long-acting Retinal Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 160. Middle East and Africa Long-acting Retinal Drugs Sales Forecast by Country (2026-2035) & (Units)
Table 161. Middle East and Africa Long-acting Retinal Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 162. Global Long-acting Retinal Drugs Sales Forecast by Type (2026-2035) & (K MT)
Table 163. Global Long-acting Retinal Drugs Market Size Forecast by Type (2026-2035) & (M USD)
Table 164. Global Long-acting Retinal Drugs Price Forecast by Type (2026-2035) & (USD/KG)
Table 165. Global Long-acting Retinal Drugs Sales (K MT) Forecast by Application (2026-2035)
Table 166. Global Long-acting Retinal Drugs Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global Long-acting Retinal Drugs Market Size by Type (M USD)
Table 4. Global Long-acting Retinal Drugs Market Size by Application
Table 5. Long-acting Retinal Drugs Market Size Comparison by Region (M USD)
Table 6. Global Long-acting Retinal Drugs Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global Long-acting Retinal Drugs Sales Market Share by Manufacturers (2020-2025)
Table 8. Global Long-acting Retinal Drugs Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global Long-acting Retinal Drugs Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting Retinal Drugs as of 2025)
Table 11. Global Market Long-acting Retinal Drugs Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global Long-acting Retinal Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Long-acting Retinal Drugs Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global Long-acting Retinal Drugs Sales by Type (K MT)
Table 27. Global Long-acting Retinal Drugs Market Size by Type (M USD)
Table 28. Global Long-acting Retinal Drugs Sales (K MT) by Type (2020-2025)
Table 29. Global Long-acting Retinal Drugs Sales Market Share by Type (2020-2025)
Table 30. Global Long-acting Retinal Drugs Market Size (M USD) by Type (2020-2025)
Table 31. Global Long-acting Retinal Drugs Market Share by Type (2020-2025)
Table 32. Global Long-acting Retinal Drugs Price (USD/KG) by Type (2020-2025)
Table 33. Global Long-acting Retinal Drugs Sales (K MT) by Application
Table 34. Global Long-acting Retinal Drugs Market Size by Application
Table 35. Global Long-acting Retinal Drugs Sales by Application (2020-2025) & (K MT)
Table 36. Global Long-acting Retinal Drugs Sales Market Share by Application (2020-2025)
Table 37. Global Long-acting Retinal Drugs Market Size by Application (2020-2025) & (M USD)
Table 38. Global Long-acting Retinal Drugs Market Share by Application (2020-2025)
Table 39. Global Long-acting Retinal Drugs Sales Growth Rate by Application (2020-2025)
Table 40. Global Long-acting Retinal Drugs Sales by Region (2020-2025) & (K MT)
Table 41. Global Long-acting Retinal Drugs Sales Market Share by Region (2020-2025)
Table 42. Global Long-acting Retinal Drugs Market Size by Region (2020-2025) & (M USD)
Table 43. Global Long-acting Retinal Drugs Market Size by Region (2020-2025)
Table 44. North America Long-acting Retinal Drugs Sales by Country (2020-2025) & (K MT)
Table 45. North America Long-acting Retinal Drugs Market Size by Country (2020-2025) & (M USD)
Table 46. Europe Long-acting Retinal Drugs Sales by Country (2020-2025) & (K MT)
Table 47. Europe Long-acting Retinal Drugs Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific Long-acting Retinal Drugs Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific Long-acting Retinal Drugs Market Size by Region (2020-2025) & (M USD)
Table 50. South America Long-acting Retinal Drugs Sales by Country (2020-2025) & (K MT)
Table 51. South America Long-acting Retinal Drugs Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa Long-acting Retinal Drugs Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa Long-acting Retinal Drugs Market Size by Region (2020-2025) & (M USD)
Table 54. Global Long-acting Retinal Drugs Production (K MT) by Region(2020-2025)
Table 55. Global Long-acting Retinal Drugs Revenue (US$ Million) by Region (2020-2025)
Table 56. Global Long-acting Retinal Drugs Revenue Market Share by Region (2020-2025)
Table 57. Global Long-acting Retinal Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America Long-acting Retinal Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe Long-acting Retinal Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan Long-acting Retinal Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China Long-acting Retinal Drugs Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Bayer Basic Information
Table 63. Bayer Long-acting Retinal Drugs Product Overview
Table 64. Bayer Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Bayer Business Overview
Table 66. Bayer SWOT Analysis
Table 67. Bayer Recent Developments
Table 68. F. Hoffmann-La Roche Basic Information
Table 69. F. Hoffmann-La Roche Long-acting Retinal Drugs Product Overview
Table 70. F. Hoffmann-La Roche Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. F. Hoffmann-La Roche Business Overview
Table 72. F. Hoffmann-La Roche SWOT Analysis
Table 73. F. Hoffmann-La Roche Recent Developments
Table 74. Novartis Basic Information
Table 75. Novartis Long-acting Retinal Drugs Product Overview
Table 76. Novartis Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. Novartis Business Overview
Table 78. Novartis SWOT Analysis
Table 79. Novartis Recent Developments
Table 80. Regeneron Basic Information
Table 81. Regeneron Long-acting Retinal Drugs Product Overview
Table 82. Regeneron Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Regeneron Business Overview
Table 84. Regeneron Recent Developments
Table 85. Merck Basic Information
Table 86. Merck Long-acting Retinal Drugs Product Overview
Table 87. Merck Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. Merck Business Overview
Table 89. Merck Recent Developments
Table 90. Takeda Basic Information
Table 91. Takeda Long-acting Retinal Drugs Product Overview
Table 92. Takeda Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Takeda Business Overview
Table 94. Takeda Recent Developments
Table 95. Teva Pharmaceutical Basic Information
Table 96. Teva Pharmaceutical Long-acting Retinal Drugs Product Overview
Table 97. Teva Pharmaceutical Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Teva Pharmaceutical Business Overview
Table 99. Teva Pharmaceutical Recent Developments
Table 100. ThromboGenics Basic Information
Table 101. ThromboGenics Long-acting Retinal Drugs Product Overview
Table 102. ThromboGenics Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. ThromboGenics Business Overview
Table 104. ThromboGenics Recent Developments
Table 105. Janssen Pharmaceuticals (Johnson and Johnson) Basic Information
Table 106. Janssen Pharmaceuticals (Johnson and Johnson) Long-acting Retinal Drugs Product Overview
Table 107. Janssen Pharmaceuticals (Johnson and Johnson) Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Janssen Pharmaceuticals (Johnson and Johnson) Business Overview
Table 109. Janssen Pharmaceuticals (Johnson and Johnson) Recent Developments
Table 110. Oxurion NV Basic Information
Table 111. Oxurion NV Long-acting Retinal Drugs Product Overview
Table 112. Oxurion NV Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. Oxurion NV Business Overview
Table 114. Oxurion NV Recent Developments
Table 115. Allergan Basic Information
Table 116. Allergan Long-acting Retinal Drugs Product Overview
Table 117. Allergan Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Allergan Business Overview
Table 119. Allergan Recent Developments
Table 120. MeiraGTx Limited Basic Information
Table 121. MeiraGTx Limited Long-acting Retinal Drugs Product Overview
Table 122. MeiraGTx Limited Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. MeiraGTx Limited Business Overview
Table 124. MeiraGTx Limited Recent Developments
Table 125. OncoGene Pharmaceuticals Basic Information
Table 126. OncoGene Pharmaceuticals Long-acting Retinal Drugs Product Overview
Table 127. OncoGene Pharmaceuticals Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. OncoGene Pharmaceuticals Business Overview
Table 129. OncoGene Pharmaceuticals Recent Developments
Table 130. AbbVie Inc. Basic Information
Table 131. AbbVie Inc. Long-acting Retinal Drugs Product Overview
Table 132. AbbVie Inc. Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 133. AbbVie Inc. Business Overview
Table 134. AbbVie Inc. Recent Developments
Table 135. Alcon Inc. Basic Information
Table 136. Alcon Inc. Long-acting Retinal Drugs Product Overview
Table 137. Alcon Inc. Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 138. Alcon Inc. Business Overview
Table 139. Alcon Inc. Recent Developments
Table 140. Alimera Sciences Inc. Basic Information
Table 141. Alimera Sciences Inc. Long-acting Retinal Drugs Product Overview
Table 142. Alimera Sciences Inc. Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 143. Alimera Sciences Inc. Business Overview
Table 144. Alimera Sciences Inc. Recent Developments
Table 145. Bausch Health Co. Inc. Basic Information
Table 146. Bausch Health Co. Inc. Long-acting Retinal Drugs Product Overview
Table 147. Bausch Health Co. Inc. Long-acting Retinal Drugs Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 148. Bausch Health Co. Inc. Business Overview
Table 149. Bausch Health Co. Inc. Recent Developments
Table 150. Global Long-acting Retinal Drugs Sales Forecast by Region (2026-2035) & (K MT)
Table 151. Global Long-acting Retinal Drugs Market Size Forecast by Region (2026-2035) & (M USD)
Table 152. North America Long-acting Retinal Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 153. North America Long-acting Retinal Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 154. Europe Long-acting Retinal Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 155. Europe Long-acting Retinal Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 156. Asia Pacific Long-acting Retinal Drugs Sales Forecast by Region (2026-2035) & (K MT)
Table 157. Asia Pacific Long-acting Retinal Drugs Market Size Forecast by Region (2026-2035) & (M USD)
Table 158. South America Long-acting Retinal Drugs Sales Forecast by Country (2026-2035) & (K MT)
Table 159. South America Long-acting Retinal Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 160. Middle East and Africa Long-acting Retinal Drugs Sales Forecast by Country (2026-2035) & (Units)
Table 161. Middle East and Africa Long-acting Retinal Drugs Market Size Forecast by Country (2026-2035) & (M USD)
Table 162. Global Long-acting Retinal Drugs Sales Forecast by Type (2026-2035) & (K MT)
Table 163. Global Long-acting Retinal Drugs Market Size Forecast by Type (2026-2035) & (M USD)
Table 164. Global Long-acting Retinal Drugs Price Forecast by Type (2026-2035) & (USD/KG)
Table 165. Global Long-acting Retinal Drugs Sales (K MT) Forecast by Application (2026-2035)
Table 166. Global Long-acting Retinal Drugs Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Long-acting Retinal Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Long-acting Retinal Drugs Market Size (M USD), 2025-2035
Figure 5. Global Long-acting Retinal Drugs Market Size (M USD) (2020-2035)
Figure 6. Global Long-acting Retinal Drugs Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Long-acting Retinal Drugs Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Long-acting Retinal Drugs Product Life Cycle
Figure 13. Long-acting Retinal Drugs Sales Share by Manufacturers in 2025
Figure 14. Global Long-acting Retinal Drugs Revenue Share by Manufacturers in 2025
Figure 15. Long-acting Retinal Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Long-acting Retinal Drugs Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Long-acting Retinal Drugs Revenue in 2025
Figure 18. Industry Chain Map of Long-acting Retinal Drugs
Figure 19. Global Long-acting Retinal Drugs Market PEST Analysis
Figure 20. Global Long-acting Retinal Drugs Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Long-acting Retinal Drugs Market Share by Type
Figure 27. Sales Market Share of Long-acting Retinal Drugs by Type (2020-2025)
Figure 28. Sales Market Share of Long-acting Retinal Drugs by Type in 2025
Figure 29. Market Share of Long-acting Retinal Drugs by Type (2020-2025)
Figure 30. Market Share of Long-acting Retinal Drugs by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Long-acting Retinal Drugs Market Share by Application
Figure 33. Global Long-acting Retinal Drugs Sales Market Share by Application (2020-2025)
Figure 34. Global Long-acting Retinal Drugs Sales Market Share by Application in 2025
Figure 35. Global Long-acting Retinal Drugs Market Share by Application (2020-2025)
Figure 36. Global Long-acting Retinal Drugs Market Share by Application in 2025
Figure 37. Global Long-acting Retinal Drugs Sales Growth Rate by Application (2020-2025)
Figure 38. Global Long-acting Retinal Drugs Sales Market Share by Region (2020-2025)
Figure 39. Global Long-acting Retinal Drugs Market Size by Region (2020-2025)
Figure 40. North America Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Long-acting Retinal Drugs Sales Market Share by Country in 2024
Figure 43. North America Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Long-acting Retinal Drugs Market Size by Country in 2024
Figure 45. U.S. Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Long-acting Retinal Drugs Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Long-acting Retinal Drugs Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Long-acting Retinal Drugs Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Long-acting Retinal Drugs Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Long-acting Retinal Drugs Sales Market Share by Country in 2024
Figure 53. Europe Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Long-acting Retinal Drugs Market Size by Country in 2024
Figure 55. Germany Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Long-acting Retinal Drugs Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Long-acting Retinal Drugs Sales Market Share by Region in 2024
Figure 67. Asia Pacific Long-acting Retinal Drugs Market Size by Region in 2024
Figure 68. China Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Long-acting Retinal Drugs Sales and Growth Rate (K MT)
Figure 79. South America Long-acting Retinal Drugs Sales Market Share by Country in 2024
Figure 80. South America Long-acting Retinal Drugs Market Size and Growth Rate (M USD)
Figure 81. South America Long-acting Retinal Drugs Market Size by Country in 2024
Figure 82. Brazil Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Long-acting Retinal Drugs Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Long-acting Retinal Drugs Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Long-acting Retinal Drugs Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Long-acting Retinal Drugs Market Size by Region in 2024
Figure 92. Saudi Arabia Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Long-acting Retinal Drugs Production Market Share by Region (2020-2025)
Figure 103. North America Long-acting Retinal Drugs Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Long-acting Retinal Drugs Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Long-acting Retinal Drugs Production (K MT) Growth Rate (2020-2025)
Figure 106. China Long-acting Retinal Drugs Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Long-acting Retinal Drugs Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Long-acting Retinal Drugs Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Long-acting Retinal Drugs Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Long-acting Retinal Drugs Market Share Forecast by Type (2026-2035)
Figure 111. Global Long-acting Retinal Drugs Sales Forecast by Application (2026-2035)
Figure 112. Global Long-acting Retinal Drugs Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of Long-acting Retinal Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Long-acting Retinal Drugs Market Size (M USD), 2025-2035
Figure 5. Global Long-acting Retinal Drugs Market Size (M USD) (2020-2035)
Figure 6. Global Long-acting Retinal Drugs Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Long-acting Retinal Drugs Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global Long-acting Retinal Drugs Product Life Cycle
Figure 13. Long-acting Retinal Drugs Sales Share by Manufacturers in 2025
Figure 14. Global Long-acting Retinal Drugs Revenue Share by Manufacturers in 2025
Figure 15. Long-acting Retinal Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market Long-acting Retinal Drugs Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by Long-acting Retinal Drugs Revenue in 2025
Figure 18. Industry Chain Map of Long-acting Retinal Drugs
Figure 19. Global Long-acting Retinal Drugs Market PEST Analysis
Figure 20. Global Long-acting Retinal Drugs Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global Long-acting Retinal Drugs Market Share by Type
Figure 27. Sales Market Share of Long-acting Retinal Drugs by Type (2020-2025)
Figure 28. Sales Market Share of Long-acting Retinal Drugs by Type in 2025
Figure 29. Market Share of Long-acting Retinal Drugs by Type (2020-2025)
Figure 30. Market Share of Long-acting Retinal Drugs by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global Long-acting Retinal Drugs Market Share by Application
Figure 33. Global Long-acting Retinal Drugs Sales Market Share by Application (2020-2025)
Figure 34. Global Long-acting Retinal Drugs Sales Market Share by Application in 2025
Figure 35. Global Long-acting Retinal Drugs Market Share by Application (2020-2025)
Figure 36. Global Long-acting Retinal Drugs Market Share by Application in 2025
Figure 37. Global Long-acting Retinal Drugs Sales Growth Rate by Application (2020-2025)
Figure 38. Global Long-acting Retinal Drugs Sales Market Share by Region (2020-2025)
Figure 39. Global Long-acting Retinal Drugs Market Size by Region (2020-2025)
Figure 40. North America Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America Long-acting Retinal Drugs Sales Market Share by Country in 2024
Figure 43. North America Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America Long-acting Retinal Drugs Market Size by Country in 2024
Figure 45. U.S. Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada Long-acting Retinal Drugs Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada Long-acting Retinal Drugs Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico Long-acting Retinal Drugs Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico Long-acting Retinal Drugs Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe Long-acting Retinal Drugs Sales Market Share by Country in 2024
Figure 53. Europe Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe Long-acting Retinal Drugs Market Size by Country in 2024
Figure 55. Germany Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific Long-acting Retinal Drugs Sales and Growth Rate (K MT)
Figure 66. Asia Pacific Long-acting Retinal Drugs Sales Market Share by Region in 2024
Figure 67. Asia Pacific Long-acting Retinal Drugs Market Size by Region in 2024
Figure 68. China Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America Long-acting Retinal Drugs Sales and Growth Rate (K MT)
Figure 79. South America Long-acting Retinal Drugs Sales Market Share by Country in 2024
Figure 80. South America Long-acting Retinal Drugs Market Size and Growth Rate (M USD)
Figure 81. South America Long-acting Retinal Drugs Market Size by Country in 2024
Figure 82. Brazil Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa Long-acting Retinal Drugs Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa Long-acting Retinal Drugs Sales Market Share by Region in 2024
Figure 90. Middle East and Africa Long-acting Retinal Drugs Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa Long-acting Retinal Drugs Market Size by Region in 2024
Figure 92. Saudi Arabia Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa Long-acting Retinal Drugs Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa Long-acting Retinal Drugs Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global Long-acting Retinal Drugs Production Market Share by Region (2020-2025)
Figure 103. North America Long-acting Retinal Drugs Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe Long-acting Retinal Drugs Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan Long-acting Retinal Drugs Production (K MT) Growth Rate (2020-2025)
Figure 106. China Long-acting Retinal Drugs Production (K MT) Growth Rate (2020-2025)
Figure 107. Global Long-acting Retinal Drugs Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global Long-acting Retinal Drugs Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global Long-acting Retinal Drugs Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global Long-acting Retinal Drugs Market Share Forecast by Type (2026-2035)
Figure 111. Global Long-acting Retinal Drugs Sales Forecast by Application (2026-2035)
Figure 112. Global Long-acting Retinal Drugs Market Share Forecast by Application (2026-2035)
